Notes from the field: rotavirus vaccine administration errors--United States, 2006-2013.
Two live rotavirus oral vaccines, RotaTeq (RV5) (Merck & Co., Inc.) and Rotarix (RV1) (GlaxoSmithKline Biologicals), are approved for prevention of rotavirus gastroenteritis and recommended at ages 2, 4 (RV5/RV1), and 6 (RV5) months by the Advisory Committee on Immunization Practices. Because most childhood vaccines are injectable, vaccination providers might have less experience administering oral vaccines. To assess that hypothesis, CDC searched for reports to the Vaccine Adverse Event Reporting System (VAERS) of rotavirus vaccine administration errors involving injection and eye splashes in the United States during the period January 1, 2006-August 1, 2013. A total of 66 reports were found.
Beth F
BF
Hibbs
Elaine R
ER
Miller
Tom
T
Shimabukuro
D000284:Administration, Oral; D016907:Adverse Drug Reaction Reporting Systems; D002487:Centers for Disease Control and Prevention, U.S.; D005131:Eye Injuries / Q000139:chemically induced; D006801:Humans; D007223:Infant; D007267:Injections / Q000009:adverse effects / Q000706:statistics & numerical data; D019300:Medical Errors / Q000706:statistics & numerical data*; D012400:Rotavirus Infections / Q000517:prevention & control*; D022243:Rotavirus Vaccines / Q000008:administration & dosage* / Q000009:adverse effects; D014481:United States; D062690:Vaccines, Live, Unattenuated / Q000008:administration & dosage / Q000009:adverse effects
D022243:Rotavirus Vaccines; D062690:Vaccines, Live, Unattenuated